From Auto To Allo: Poseida Tries To Pick The Winning CAR-T Team

 
• By Alaric DeArment

The company is winding down its autologous myeloma CAR-T program as competition in that market heats up and interest in off-the-shelf CAR-Ts grows.

3d illustration of T cells attacking a cancer cell
In its third quarter earnings, Poseida said it would wind down its autologous CAR-T for myeloma and refocus on off-the-shelf therapy • Source: Shutterstock

More from Anticancer

More from Therapy Areas